Tag Archives: Jason Mccarthy

Maxim Group Gives a Buy Rating to OncoSec Medical

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to OncoSec Medical (NASDAQ: ONCS), with a price target of $5. The company’s shares opened today at $1.89. McCarthy observed: “Oncosec announced that the P2b study

Maxim Group Releases a Buy Rating on Juno Therapeutics

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Juno Therapeutics (NASDAQ: JUNO), with a price target of $56. The company’s shares closed yesterday at $45.75. McCarthy observed: “The American Society of Hematology (ASH)

Maxim Group Gives a Buy Rating to ADMA Biologics

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to ADMA Biologics (NASDAQ: ADMA), with a price target of $8. The company’s shares opened today at $2.76. McCarthy noted: “Recent financing: ADMA completed an equity

Maxim Group Initiates a Buy Rating on Cancer Genetics

Cancer Genetics (NASDAQ: CGIX) received a Buy rating and a $6 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $2.15. McCarthy wrote: “As the paradigm in oncology shifts to immune therapy with CAR-T,

Maxim Group Gives a Buy Rating to Biolinerx

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Biolinerx (NASDAQ: BLRX), with a price target of $3. The company’s shares opened today at $1.15. McCarthy said: “BiolineRx announced long-term follow-up data from the

Why Did Maxim Group Upgrade BioLife Solutions’ Stock?

BioLife Solutions (NASDAQ: BLFS) received a Buy rating and an $8 price target from Maxim Group analyst Jason McCarthy today. The company’s shares opened today at $5.67. McCarthy wrote: “Biolife announced that the company executed a new agreement to supply